Used as a targeted protein degrader in cancer research, particularly as a cereblon E3 ligase modulator. It functions by binding to specific disease-causing proteins and promoting their ubiquitination and subsequent degradation by the cell's proteasome system.

This compound is designed to target oncogenic or dysregulated proteins involved in hematological malignancies and solid tumors, making it a valuable tool in developing therapies for conditions like multiple myeloma and other cancers.

Its structure enables enhanced selectivity and cellular permeability, supporting its use in preclinical studies to evaluate efficacy, pharmacokinetics, and mechanism of action in protein degradation pathways.